Lead Product(s) : BAN1503
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $1,350.0 million
Deal Type : Licensing Agreement
Bio Arctic, BMS Ink Global License Deal for Pyro Glutamate-Amyloid-Beta Antibody
Details : Under the licensing agreement, BMS will become solely responsible for the development and any subsequent commercialization of BAN1503 and BAN2803 and related products worldwide.
Product Name : BAN1503
Product Type : Antibody
Upfront Cash : $100.0 million
February 20, 2025
Lead Product(s) : BAN1503
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $1,350.0 million
Deal Type : Licensing Agreement
Lead Product(s) : BAN1503
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $1,125.0 million
Deal Type : Licensing Agreement
BioArctic Licenses PyroGlutamate-Aβ Antibody Program To Bristol Myers Squibb Globally
Details : Under the license agreement, BMS will become solely responsible for the development and any subsequent commercialization of BAN1503, which is being evaluated for Alzheimer Disease.
Product Name : BAN1503
Product Type : Antibody
Upfront Cash : $100.0 million
December 19, 2024
Lead Product(s) : BAN1503
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $1,125.0 million
Deal Type : Licensing Agreement
Lead Product(s) : BAN2802
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Eisai Inc
Deal Size : Undisclosed
Deal Type : Agreement
BioArctic and Eisai Sign Research Evaluation Agreement Regarding BAN2802
Details : The agreement aims to evaluate BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
Product Name : BAN2802
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 20, 2024
Lead Product(s) : BAN2802
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Eisai Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : IRL757
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IRLAB’s Drug Candidate IRL757 is Phase I Ready
Details : IRLAB’s drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I trial studies. It has shown tremendous potential in this indication in the preclinical program of Parkinson's Disease and other neurolog...
Product Name : IRL757
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : IRL757
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IRL1117
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IRLAB Selects IRL1117 As Drug Candidate to Develop a New Treatment for Parkinson’s Disease
Details : IRL1117 is an orally available and potent dopamine D1 and D2 receptor agonist that has demonstrated rapid onset and more than 10 hours of sustained efficacy in preclinical studies.
Product Name : IRL1117
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2023
Lead Product(s) : IRL1117
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACD680
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AlzeCure Selects CD and Enters Next Development Phase with Alzstatin ACD680 Against Alzheimer’s
Details : ACD680 (alzstatin) is a gamma-secretase modulator (GSM), which constitutes a promising class of small-molecule Aβ42-lowering anti-amyloidogenic substances for preventive and disease-modifying treatment of Alzheimer's disease.
Product Name : ACD680
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : ACD680
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IRL757
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to evaluate IRLAB’s neuropsychiatric programs IRL757 and IRL942. Drug candidate IRL757 is being developed as a treatment for apathy in neurological disorders such as Parkinson’s, Alzheimer’s disease with a once-daily oral adminis...
Product Name : IRL757
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : IRL757
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : AC-0027875
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®.
Product Name : AC-0027875
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : AC-0027875
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PD-BT2238
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioarctic Expands Portfolio With Alpha-synuclein Brain Transporter Project
Details : The PD-BT2238 project is a second-generation alpha-synuclein antibody, combining an oligomer-selective alpha-synuclein antibody with BioArctic's Brain Transporter technology, designed to improve brain exposure.
Product Name : PD-BT2238
Product Type : Antibody
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : PD-BT2238
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioArctic Receives New Patent In The US For Blood-brain Barrier Transport Technology
Details : Blood-brain barrier protects brain from foreign substances by restricting passage of these substances into brain. The patented technologyhas been developed to facilitate the transport of biopharmaceuticals across this barrier, thereby potentially improvi...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable